Press releaseGlobe Newswire
MaxCyte
MXCT · NASDAQ
$1.43+$0.13 (+10.00%)TodayMarket closed ·
Prev close $1.30
Latest news
- Press releaseGlobe Newswire
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
- Press releaseGlobe Newswire
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- News
MaxCyte Launches CHANGE-seq-BE And ONE-seq-BE Off-Target Nomination Assays
- Press releaseGlobe Newswire
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
MaxCyte Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
- Press releaseGlobe Newswire
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsRishabh Mishra
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED)
- NewsAvi Kapoor
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
- News
Earnings Scheduled For May 12, 2026
- Press releaseGlobe Newswire
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
- Press releaseBusiness Wire
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
- Press releaseBusiness Wire
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.